Fosrenol (Lanthanum Carbonate) Patent Expiration, LOE Window & CMS Spending
Fosrenol (Lanthanum Carbonate) by Takeda: FDA Orange Book LOE 2030-12-01, 4 AB generics, $6.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Takeda |
| FDA Application & Pathway | N021468 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-12-01 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $6.5M |
| 2024 Medicare Part D Spend | $5.3M |
| 2024 Medicaid Spend | $1.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.